Current Report Filing (8-k)
23 Janeiro 2023 - 6:14PM
Edgar (US Regulatory)
0000064803
false
0000064803
2023-01-18
2023-01-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): |
January 23, 2023 (January 18, 2023) |
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
Delaware |
001-01011 |
05-0494040 |
(State or other jurisdiction of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
|
One CVS Drive, Woonsocket, Rhode Island 02895
(Address of principal executive offices) (Zip
Code)
Registrant’s telephone number, including
area code: (401) 765-1500
Former name or former address, if changed since
last report: N/A
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, par value $0.01 per share |
CVS |
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
|
|
|
|
|
|
Emerging growth company |
☐ |
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
☐ |
Section 5 - Corporate Governance and Management
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 18, 2023, Alan M. Lotvin, M.D., Executive Vice President and
President, Pharmacy Services, advised CVS Health Corporation of his intention to retire in April 2023.
Section 7 - Regulation FD
Item 7.01 Regulation FD Disclosure.
On January 23, 2023, CVS Health Corporation announced
that it has appointed J. David Joyner as its new President, Pharmacy Services, effective January 30, 2023.
On January 23, 2023, CVS Health Corporation issued
a press release announcing Dr. Lotvin’s retirement, described in Item 5.02 above, and Mr. Joyner’s appointment. A copy of
that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 7.01 by reference.
The information in this Item 7.01 of this Current
Report on Form 8-K and the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or
be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
INDEX TO EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
CVS HEALTH CORPORATION |
|
|
|
Date: January 23, 2023 |
By: |
/s/ Colleen M. McIntosh |
|
|
Colleen M. McIntosh |
|
|
Senior Vice President, Secretary and
Chief Governance Officer |
|
|
|
CVS Health (NYSE:CVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
CVS Health (NYSE:CVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024